Charles River Laboratories International, Inc. (NYSE:CRL) Position Increased by Iridian Asset Management LLC CT

Iridian Asset Management LLC CT increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 18.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,419 shares of the medical research company's stock after buying an additional 9,454 shares during the period. Charles River Laboratories International comprises 2.9% of Iridian Asset Management LLC CT's portfolio, making the stock its 12th largest holding. Iridian Asset Management LLC CT owned 0.12% of Charles River Laboratories International worth $9,094,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in CRL. Rothschild Investment LLC increased its position in Charles River Laboratories International by 480.0% during the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after buying an additional 144 shares in the last quarter. HM Payson & Co. acquired a new stake in shares of Charles River Laboratories International in the first quarter worth $31,000. Optiver Holding B.V. acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth $37,000. GeoWealth Management LLC increased its position in shares of Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after acquiring an additional 190 shares in the last quarter. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth $48,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president owned 19,513 shares of the company's stock, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL traded down $3.88 on Friday, reaching $159.78. 518,978 shares of the company's stock were exchanged, compared to its average volume of 1,029,720. The firm has a market capitalization of $7.85 billion, a price-to-earnings ratio of -245.81, a PEG ratio of 5.38 and a beta of 1.49. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The business's 50-day moving average is $144.04 and its two-hundred day moving average is $152.01. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.78.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The firm's revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.27 earnings per share. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Upgrades and Downgrades

CRL has been the subject of several recent research reports. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their target price for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. Citigroup upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and upped their target price for the company from $150.00 to $200.00 in a research note on Wednesday. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a research note on Wednesday, May 14th. Finally, Barclays upped their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $174.54.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).